Share on

North America Infectious Disease Diagnostics Market Research Report - Segmented By Product, Application, Technology, End User & Country (the United States, Canada and Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028)

Published: March, 2023
ID: 4450
Pages: 130
Formats: report pdf report excel report power bi report ppt

North America Infectious Disease Diagnostics Market Size (2022 to 2027)

The size of the infectious diseases diagnostics market in North America is anticipated to grow at a 7.34% CAGR from 2023 to 2028. The North American market is expected to be worth USD 10.49 billion by 2028 from USD 7.36 billion in 2023.

The market for infectious disease diagnostics in the North American region is driven by factors such as the rising prevalence of infectious diseases and increasing spending on R&D to develop better solutions. Chlamydia, Influenza A and B, Staph, E. Coli, Herpes Simplex 1, Herpes Simplex 2, Shigellosis, Syphilis, Gonorrhea, Norovirus, Salmonella, Tuberculosis, Pneumonia, Hepatitis C, and HIV are a few of the major infectious diseases in the United States. In addition, technological advancements are further favoring the market growth in North America. Shifting the emphasis of healthcare providers from centralized labs to point-of-care testing to provide detailed information about the causative organism and a better understanding of diagnostics in the developed economies is anticipated to boost the market growth during the forecast period.

The various mucus samples, blood, urine, or other bodily fluids were collected for analysis using various diagnostic procedures and instruments. Due to the increasing burden of infectious diseases in North American countries, the demand for testing equipment is expected to see a spike.  Furthermore, increasing adoption of technologically advanced visual diagnostic equipment in healthcare organizations in emerging economies due to increased incidence of various infectious diseases, rising funding from North American governments, increasing focus on improving adequate reimbursement policies in developed economies, high demand for early diagnostic tests by the population are estimated to accelerate the growth rate of the market in the North American region.

However, growing healthcare costs, especially in developed economies, are expected to impact market growth during the forecast period negatively. In addition, a lack of awareness regarding infectious diseases among the population living in underdeveloped localities is further inhibiting the market's growth rate in this region.

This research report on the North American infectious disease diagnostics market has been segmented and sub-segmented into the following categories:

By Product: 

  • Instruments
  • Reagents
  • Services
  • Software

By Application: 

  • Hepatitis B
  • Hepatitis C
  • Human Immunodeficiency Virus (HIV)
  • Tuberculosis (TB)
  • Chlamydia trachomatis
  • Neisseria gonorrhoeae (CT/NG)
  • Human papillomavirus (HPV)
  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • and others (Influenza, Ebola, Typhoid, Malaria, and Dengue)

By Technology: 

  • PCR
  • INAAT
  • DNA Sequencing
  • Hybridization

By End User: 

  • Hospital
  • Laboratories

By Country: 

  • The United States
  • Canada
  • Rest of North America

Regional Analysis:

Geographically, North America held the largest share of the global IDD market in 2022. This region is projected to witness a promising growth rate during the forecast years due to the growing adoption of premium diagnostic techniques to sustain the market share of infectious disease diagnostics in a developed region. The infectious disease diagnostics market in North America was the largest in the world. The growing prevalence of infectious diseases is one of the major factors contributing significantly to the domination of the North American region in the global market. The highly developed healthcare system in the United States and Canada, numerous major national clinical laboratories, and simple access to technologically advanced instruments all contribute to the growth of the North American infectious disease diagnostics market. The United States has a well-structured healthcare system because it is a developed economy. This has aided the country's access to the diagnostic tests currently accessible on the market. Diagnostic tests help in early disease detection, which can help prevent the spread of infectious diseases.

The U.S. market had a major share of North America in 2022. The domination of the U.S. in the North American region can be attributed to the increasing number of people suffering from various infectious diseases, leading to high expenditure on the healthcare sector. According to the Centers for Disease Prevention and Control (CDC), an estimated 8916 with tuberculosis, 58371 with salmonella, 34945 with Lyme disease, and 371 with meningococcal were suffered in the U.S. in 2019. In addition, technological advancements are further accelerating the market growth in the U.S. The need to use technologically advanced medical devices in treatment procedures is growing consistently owing to the growing patient awareness regarding the availability of treatment devices. To meet the market demand and acquire a leading market share, the key competitors are adopting strategies such as collaborations, acquisitions, and grant programs such as strategic activities, along with the help of growing regulatory support and investment by the government.

Canada in North America is expected to register promising growth during the forecast period. Due to the country's numerous untapped opportunities, favorable regulatory framework, highly developed healthcare system, improved access to healthcare, and essential industries, Canada is predicted to account for a considerable share of the North American market during the forecast period. In addition, the ease of access to technologically advanced instruments due to more focus on increasing disease surveillance, which can be efficiently through more testing, led to an overall increase in the infectious disease diagnostics market in Canada.

KEY MARKET PLAYERS:

Companies playing a dominant role in the North America Infectious Diseases Diagnostics Market profiled in this report are Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, Becton, Dickinson and Company, Cepheid, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample